Gerresheimer continues expansion course

Düsseldorf (ots) -

- Prospects for 2008 confirmed
- Shareholders approve dividend payment of EUR0.40 per share

The company ended the financial year 2007 with a positive result.
In 2007 Gerresheimer achieved sales of EUR957.7m and operating
earnings (adjusted EBITDA) of EUR181.6m. For the first quarter of the
current financial year 2008, the company reports a sales increase of
18.2% to EUR239.1m, with a 20.4% increase in operating earnings
(adjusted EBITDA) to EUR43.0m.

"In the past year we have expanded our regional presence with
consistent focus on the high-profit business in specialty products
for the pharmaceutics and life-science industry. We intend to
continue this successful strategy in 2008," says Dr. Axel Herberg,
CEO of Gerresheimer AG.

At the Shareholders' Meeting in Düsseldorf today, Dr. Herberg
confirmed the positive prospects for 2008. In the coming year the
company aims to achieve sales growth of 14%-16% and an Adjusted
EBITDA margin in excess of 19%.

By a large majority the shareholders of Gerresheimer AG approved
the actions of the Management Board and Supervisory Board for the
financial year 2007 and a dividend payment of EUR0.40 per share. In
the first year after its stock-exchange flotation Gerresheimer is
therefore already distributing a sum of EUR12.6m to its shareholders.

By a large majority the shareholders also authorised the
Management Board of Gerresheimer AG to issue warrant-linked bonds and
convertible bonds up to the value of EUR500m in conjunction with the
creation of contingent capital. They thereby supported the continued
expansion course of the Düsseldorf supplier to the pharma and
life-science industry.

A large number of shareholders and shareholder representatives
attended the first Shareholders? Meeting of Gerresheimer AG after the
IPO in June 2007, so 59% of the capital stock was represented at the
Shareholders' Meeting.

Gerresheimer facts and figures

Gerresheimer employs more than 10,800 people in 41 production
locations in Europe, America and Asia. In the financial year 2007,
worldwide sales totalled EUR957.7m. The product portfolio ranges from
pharmaceutical vials made of glass and plastic to complex drug
delivery systems for the pharma and life-science industry. It
includes sterile syringes, inhalers and other system-based approaches
for safe dosage and application of medicines. The Group has a leading
position in markets which are characterised by high technical and
regulatory barriers.

Originaltext: Gerresheimer AG
digital press kits: http://www.presseportal.de/pm/9072
press kits via RSS: http://www.presseportal.de/rss/pm_9072.rss2
ISIN: DE000A0LD6E6

Presscontact:
Contact Press
Burkhard Lingenberg
Director Corporate PR & Marketing
Telephone +49 211 6181-250
Telefax +49 211 6181-241
e-mail b.lingenberg@gerresheimer.com

Contact Investor Relations
Anke Linnartz
Director Corporate Investor Relations
Telephone +49 211 6181-314
Telefax +49 211 6181-121
e-mail a.linnartz@gerresheimer.com